Genmab A (GMAB) Invested Capital (2019 - 2025)

Genmab A (GMAB) reported Invested Capital of $5.3 billion for Q4 2025, up 37571.43% quarter-over-quarter from $14.0 million in Q1 2025.

Genmab A (GMAB) Invested Capital (2019 - 2025) Analysis & Trends

Genmab A has reported Invested Capital for 3 years, with the latest figure at $5.3 billion in Q4 2025.

For the quarter ending Q4 2025, Invested Capital changed N/A year-over-year to $5.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (up 37571.43% YoY), and the FY2025 full-year result was $5.3 billion, changed N/A from the prior year.
Invested Capital for Q4 2025 stood at $5.3 billion, up from $14.0 million in the prior quarter.
The five-year high for Invested Capital was $5.3 billion in Q4 2025, with the low at $14.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	7.14 Bn
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	795.79 Mn
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	595,226.00
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	1.00 Bn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	14.38 Mn
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	19.36 Bn
9	Abivax	94.26 Bn	94.26 Bn	-	502.95 Mn
10	Genmab A	48.34 Bn	46.82 Bn	831.00 Mn	-

Download Data